Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05147350 · ClinicalTrials.gov registry record · Phase 1
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
A Phase 1 study, sponsored by Debiopharm International.
- Terminated
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT05147350: Clinical Trial Phase 1 study, sponsored by Debiopharm International.
NCT05147350 is a Phase 1 study that was terminated before completion, run by Debiopharm International. The registered enrollment target is 38 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05147350, a Phase 1 study, was terminated before completion, sponsored by Debiopharm International.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activity.
Primary Outcome
Incidence of grade 3 and above Treatment Related Emergent Adverse Events (TRAEs)
Interventions
- DRUG RP-6306 (oral PKMYT1 inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2025-02-12 |
| Phase | Phase 1 |
Why NCT05147350 stopped before completion
NCT05147350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 1 intervention - of which RP-6306 (oral PKMYT1 inhibitor) is the first listed.
NCT05147350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05147350 about?
NCT05147350 is a clinical study titled "Study of RP-6306 With FOLFIRI in Advanced Solid Tumors". The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activit...
What is the current status of trial NCT05147350?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2022-08-09. Estimated completion is 2025-02-12.
What interventions are being tested in trial NCT05147350?
The interventions under investigation include: RP-6306 (oral PKMYT1 inhibitor) (DRUG).
Who is sponsoring clinical trial NCT05147350?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05147350's enrollment target sits among peer trials
38 1197th of 2000 higher than 797 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI